How to Approach Patients with Primary Refractory DLBCL

In this episode of “The Fellow on Call,” hosts Ronak Mistry, DO; Vivek Patel, MD; and Dan Hausrath, MD; continue their discussion about management of diffuse large B-cell lymphoma (DLBCL), focusing on the primary refractory setting.

The hosts first compare the definitions for “primary refractory” versus “relapsed” disease before diving into treatment regimens for patients with primary refractory disease.

In the final half of the podcast, they discuss the role of chimeric antigen receptor (CAR)-T therapy, how they “bridge” patients to the treatment, and how they monitor patients post-CAR-T.

This podcast originally appeared on thefellowoncall.com.